TY - JOUR
T1 - Progress, challenges, and future of nanomedicine
AU - Zhang, Chenyang
AU - Yan, Liang
AU - Wang, Xin
AU - Zhu, Shuang
AU - Chen, Chunying
AU - Gu, Zhanjun
AU - Zhao, Yuliang
N1 - Funding Information:
This work was supported by the National Basic Research Program of China [ 2016YFA2021600 ]; the National Natural Science Foundation of China [ 51822207 , 51772292 , and 11621505 ]; Chinese Academy of Sciences Youth Innovation Promotion Association [ 2013007 ]; and CAS Key Research Program of Frontier Sciences [ QYZDJ-SSW-SLH022 ].
Publisher Copyright:
© 2020
PY - 2020/12
Y1 - 2020/12
N2 - Nanotherapeutics exhibit unique advantages in clinical outcomes compared with conventional small molecular drugs. The past three decades have seen intensive research in the field of nanomedicine, leading to a large number of nanomedical products commercialized globally as well as a pipeline of candidates being translated. However, the development of nanomedicine still faces poor efficacy in many applications. The key to advance the field is a deep understanding of the current barriers, addressable challenges, and future demands. Herein, we first present an overview of the more conventional nanotherapeutics that have been widely investigated so far. This is accompanied by a discussion of the next-generation precision and high-efficient nanotherapeutics, exemplified by functional nanodrugs with enhanced passive targeting, active targeting, and stimuli responsiveness. Next, we emphasize the importance of translating nanomedicine research from bench to bed, detailing issues of safety evaluation, biological fate, manufacturing, cost, and regulatory hurdles. Finally, we provide our perspectives on the challenges and opportunities awaiting scientists to advance this exciting field.
AB - Nanotherapeutics exhibit unique advantages in clinical outcomes compared with conventional small molecular drugs. The past three decades have seen intensive research in the field of nanomedicine, leading to a large number of nanomedical products commercialized globally as well as a pipeline of candidates being translated. However, the development of nanomedicine still faces poor efficacy in many applications. The key to advance the field is a deep understanding of the current barriers, addressable challenges, and future demands. Herein, we first present an overview of the more conventional nanotherapeutics that have been widely investigated so far. This is accompanied by a discussion of the next-generation precision and high-efficient nanotherapeutics, exemplified by functional nanodrugs with enhanced passive targeting, active targeting, and stimuli responsiveness. Next, we emphasize the importance of translating nanomedicine research from bench to bed, detailing issues of safety evaluation, biological fate, manufacturing, cost, and regulatory hurdles. Finally, we provide our perspectives on the challenges and opportunities awaiting scientists to advance this exciting field.
KW - Clinical translation
KW - Nanomedicine
KW - Nanotherapeutics
KW - Stimuli-responsive
UR - http://www.scopus.com/inward/record.url?scp=85093098414&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85093098414&partnerID=8YFLogxK
U2 - 10.1016/j.nantod.2020.101008
DO - 10.1016/j.nantod.2020.101008
M3 - Review article
AN - SCOPUS:85093098414
SN - 1748-0132
VL - 35
JO - Nano Today
JF - Nano Today
M1 - 101008
ER -